Clinical Trials
11 trialsNCT03737981 2026-05-01
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03516617 2026-02-09
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06238648 2024-09-26
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT01039376 2019-07-30
PROLONG
Novartis
Phase 3 Terminated
NCT00921414 2018-04-27
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
French Innovative Leukemia Organisation
Phase 3 Completed
NCT03016000 2017-07-28
Thalidomide Maintenance Treatment in DLBCL
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT00445731 2014-09-08
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
University of Minnesota
Phase NA Completed